AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

2.70USD0.00 (0.00%)Market Closed

Market Summary

USD2.700.00

Market Closed

0.00%

AYTU Stock Price

View Fullscreen

AYTU RSI Chart

AYTU Valuation

Market Cap

15.0M

Price/Earnings (Trailing)

-1.1

Price/Sales (Trailing)

0.16

EV/EBITDA

90.88

Price/Free Cashflow

1.71

AYTU Price/Sales (Trailing)

AYTU Profitability

Operating Margin

56.05%

EBT Margin

-13.45%

Return on Equity

-44.46%

Return on Assets

-10.62%

Free Cashflow Yield

58.53%

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

93.8M

Rev. Growth (Yr)

-20.85%

Rev. Growth (Qtr)

-21.54%

AYTU Earnings

Earnings (TTM)

-13.7M

Earnings Growth (Yr)

59.9%

Earnings Growth (Qtr)

-1.2K%

Breaking Down AYTU Revenue

Last 7 days

-3.2%

Last 30 days

-6.2%

Last 90 days

-6.9%

Trailing 12 Months

63.6%

How does AYTU drawdown profile look like?

AYTU Financial Health

Current Ratio

0.85

AYTU Investor Care

Shares Dilution (1Y)

47.30%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.8M	0	0	0
2023	104.1M	107.4M	101.8M	98.5M
2022	92.7M	96.7M	102.4M	105.6M
2021	57.0M	65.6M	74.0M	82.0M
2020	14.5M	27.6M	39.7M	51.7M
2019	6.5M	7.3M	7.3M	8.7M
2018	3.6M	3.7M	4.0M	4.8M
2017	3.3M	3.3M	3.3M	3.4M
2016	1.8M	2.6M	2.8M	3.1M
2015	110.2K	261.8K	721.6K	1.2M
2014	31.7K	45.3K	76.7K	92.5K
2013	33.6K	41.8K	18.1K	0
2012	0	0	17.2K	25.4K
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Aytu BioScience Inc

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

CEO	Mr. Joshua R. Disbrow
WEBSITE	https://aytubio.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	164

Aytu BioScience Inc Frequently Asked Questions

What is the ticker symbol for Aytu BioScience Inc? What does AYTU stand for in stocks?

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aytu BioScience Inc (AYTU)?

As of Fri Jul 26 2024, market cap of Aytu BioScience Inc is 15.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers.

Is Aytu BioScience Inc a good stock to buy?

The fair value guage provides a quick view whether AYTU is over valued or under valued. Whether Aytu BioScience Inc is cheap or expensive depends on the assumptions which impact Aytu BioScience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AYTU.

What is Aytu BioScience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AYTU's PE ratio (Price to Earnings) is -1.1 and Price to Sales (PS) ratio is 0.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.